IL-6-induced stimulation of c-Myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1

Cancer Research

Volumn 68, Issue 24, 2008, Pages 10215-10222

  Shi, Yijiang ^a,b   Frost, Patrick J ^a,b   Hoang, Bao Q ^a,b   Benavides, Angelica ^a,b   Sharma, Sanjai ^a,b   Gera, Joseph F ^a,b   Lichtenstein, Alan K ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTERNAL RIBOSOME ENTRY SITE; MULTIPLE MYELOMA; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN RNA BINDING; RNA INTERFERENCE; RNA TRANSLATION;

GENES, MYC; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-MYC; RIBOSOMES; TRANSFECTION;

EID: 57749102689     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1066     Document Type: Article

References (37)

1. Marcu KB, Bossone SA, Patel AJ. Myc function and regulation. Annu Rev Biochem 1992;61:809-60.
2. Gaidano G, Dalla Favera R. Molecular biology of lymphomas. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. Philadelphia: Lippincott-Raven. P 1997; p. 2131-45.
3. Gado K, Silva S, Paloczi K, Domjan G, Falus A. Mouse plasmacytoma: an experimental model of human multiple myeloma. Haematologica 2001;86:227-36.
4. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001;20:5611-22.
5. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-56.
6. Melamed D, Tiefenbrun N, Yarden A, Kimchi A. Interferons and interleukin-6 suppress the DNA-binding activity of E2F in growth-sensitive hematopoietic cells. Mol Cell Biol 1993;13:5255-65.
7. Paulin FE, West MJ, Sullivan NF, Whitney RL, Lyne L, Willis AE. Aberrant translational control of the c-myc gene in multiple myeloma. Oncogene 1996;13:505-12.
8. Chappell SA, LeQuesne JP, Paulin FE, et al. A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation. Oncogene 2000;19:4437-40.
9. Baird SD, Turcotte M, Korneluk RG, Holcik M. Searching for IRES. RNA 2006;10:1755-85.
10. Hellen CU, Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev 2001;15:1593-612.
11. Stoneley M, Willis AE. Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression. Oncogene 2004;23:3200-7.
12. Xu FH, Sharma S, Gardner A, et al. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood 1998;92:241-51.
13. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995;86:685-91.
14. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem 2005;280:10964-73.
15. Frost P, Shi Y, Hoang B, Lichtenstein A. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple Myeloma cells. Oncogene 2007;26:2255-62.
16. Shi Y, Reiman T, Li W, et al. Targeting aurora kinases as therapy in multiple myeloma. Blood 2007;109:3915-21.
17. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004;279:2737-46.
18. Iwabuchi K, Li B, Bartel P, Fields S. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization. Oncogene 1993;8:1693-6.
19. Tenenbaum SA, Lager PJ, Carson CC, Keene JD. Ribonomics: identifying mRNA subsets in mRNP complexes using antibodies to RNA-binding proteins and genomic arrays. Methods 2002;26:191-8.
20. Weicker M, Orian A, Jin J, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-myc protein degradation. Proc Natl Acad Sci U S A 2004;101:9085-90.
21. Marderosian M, Sharma A, Funk AP, et al. Tristetraprolin regulates cyclin D1 and c-myc mRNA stability in response to rapamycin in an AKT-dependent manner via p38 signaling. Oncogene 2006;25:6277-90.
22. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003;101:3126-35.
23. Liu P, Quam L, Billadeau D, et al. Activating mutations of N- and K-ras in multiple myeloma show distinct clinical associations: analysis of the ECOG phase III trial. Blood 1996;88:2699-706.
24. Billadeau D, Jelinek DF, Shah N, LeBien TW, Van Ness B. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res 1995;55:3640-6.
25. Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem 2002;277:15712-20.
26. Zong Q, Schummer M, Hood L, Morris DR. Messenger RNA translation state: the second dimension of high-throughput expression screening. Proc Natl Acad Sci U S A 1999;96:10632-6.
27. Jo OD, Martin J, Bernath A, Masri J, Lichtenstein A, Gera J. hnRNP A1 reglates cyclin Da and c-myc IRES function through AKT signaling. J Biol Chem 2008;283:23274-87.
28. Allemand E, Guil S, Myers M, Moscat J, Caceres JF, Krainer AR. Regulation of heterogeneous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proc Natl Acad Sci U S A 2005;102:3605-10.
29. Bonnal S, Pileur F, Orsini C, et al. Heterogeneous nuclear ribonucleoprotein A1 is a novel internal ribosome entry site trans-acting factor that modulates alternative initiation of translation of the fibroblast growth factor 2 mRNA. J Biol Chem 2005;280:4144-53.
30. Lewis SM, Veyrier A, Hosszu Ungureanu N, Bonnal S, Vagner S, Holcik M. Subcellular relocalization of a transacting factor regulates XIAP IRES-dependent translation. Mol Biol Cell 2007;18:1302-11.
31. Siomi MC, Eder PS, Kataoka N, Wan L, Liu Q, Dreyfuss G. Transportin-mediated nuclear import of heterogeneous nuclear RNP proteins. J Cell Biol 1997;138:1181-92.
32. Michael WM, Choi M, Dreyfuss G. A nuclear export signal in hnRNP A1: a signal-mediated, temperature-dependent nuclear protein export pathway. Cell 1995;83:415-22.
33. Buxade M, Parra JL, Rousseau S, et al. The Mnks are novel components in the control of TNF α biosynthesis and phosphorylate and regulate hnRNP A1. Immunity 2005;23:177-89.
34. van der Houven van Oordt W, Diaz-Meco MT, Lozano J, Krainer AR, Moscat J, Caceres JF. The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. J Cell Biol 2000;149:307-16.
35. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/ threonine kinases Mnk1 and Mnk2. EMBO J 1997;16:1909-20.
36. Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a myc transgene induces multiple Myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008;13:167-80.
37. Avet-Loiseau H, Gerson F, Magrangeas F, Minivieele S, Harouseau JL, Bataille R. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple Myeloma tumors. Blood 2001;98:3082-6.